Last reviewed · How we verify
NCT04450771
Confirming the Efficacy/Mechanism of Family Therapy for Children With Low Weight ARFID
NA trial testing Family-based Treatment for ARFID in Avoidant/Restrictive Food Intake Disorder in 98 participants. Completed in 16 January 2026.
13 July 2025
Quick facts
| Lead sponsor | Stanford University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 98 |
| Start date | 1 December 2020 |
| Primary completion | 13 July 2025 |
| Estimated completion | 16 January 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Family-based Treatment for ARFID
- Manualized Non-Specific Usual Care for ARFID
Conditions studied
- Avoidant/Restrictive Food Intake Disorder — all drugs for Avoidant/Restrictive Food Intake Disorder →
Sponsor
Stanford University
Who can join
Adults 6 to 12, any sex, with Avoidant/Restrictive Food Intake Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is examining the efficacy and mechanism of family therapy compared to usual care for children between the ages of 6 and 12 who are diagnosed with Avoidant/Restrictive Food Intake Disorder. Preliminary data suggest that family therapy is superior to usual care and that improvement in parental self-efficacy related to feeding their children is the mechanism of treatment. In addition, this study will attempt to identify specific patient groups who respond to family therapy.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Protocol for a randomized clinical trial for Avoidant Restrictive Food Intake Disorder (ARFID) in low-weight youth.
Van Wye E, Matheson B, Citron K, Yang HJ, et al · · 2023 · cited 6× · PMID 36460266 · DOI 10.1016/j.cct.2022.107036 -
Pilot Case Series Studying a Psychoeducational and Motivational Treatment for Children With Low-Weight Avoidant Restrictive Food Intake Disorder.
Matheson B, Datta N, Van Wye E, Yang HJ, et al · · 2024 · cited 5× · PMID 39120094 · DOI 10.1002/eat.24273 -
Family vs Individual Treatment for Children With Avoidant/Restrictive Food Intake Disorder: A Randomized Clinical Trial.
Lock J, Matheson B, Jo B, Bohon C, et al · · 2026 · PMID 42019720 · DOI 10.1016/j.jaac.2026.04.007 -
Family-Based Treatment for Avoidant/Restrictive Food Intake Disorder: Last-Session Reflections.
Datta N, Boyce H, West C, Liu A, et al · · 2026 · PMID 41897987 · DOI 10.3390/bs16030325
Verify or expand the search:
- PubMed search for NCT04450771
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Stanford University trials
Trials by the same sponsor.
- NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
- NCT04225949 — Patients Understanding of PROM Graphs · NA · withdrawn
- NCT06273098 — School-Based Bladder Health Intervention · NA · withdrawn
- NCT04652635 — Management of Nailbed Injuries · NA · withdrawn
- NCT05443503 — Stanford Spine Keeper - Managing Your Low Back Pain · NA · suspended
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04450771 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Stanford University
- Last refreshed: 2 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04450771.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing